05/08/2020
Cell Lab | Anapharm Bioanalytics expands its laboratory capabilities
We are glad to inform you that a cell lab has recently been built at our facilities in Barcelona. Such expansion of our services’ portfolio is in response to client’s growing demand for cell-based assays and is aligned with Anapharm’s grow strategy towards providing effective solutions for its clients worldwide.
Our brand new cell lab capabilities will enable the development and validation of a variety of assays such as Cell Proliferation, Ligand Stimulated Cell Signalling, Protein Secretion, Reporter Gene, NAbs, etc. The results’ readouts include Absorbance, Fluorescence and Luminescence.
”This is an important addition to our offering and a step forward towards providing better assistance to our clients’ drug Development programs” said Dr. Salvatore Scarpaci, Large Molecule Bioanalysis Director at Anapharm Bioanalytics.
We strive to exceed Sponsor’s expectations by delivering great value services and we look forward to supporting our clients’ evolving needs time after time.
If you are interested in having additional details please let us know.
About Anapharm Bioanalytics
15+ years’ experience in LBA assays for antibodies and biomarkers and 30+ years’ experience in LC/MS-MS bioanalysis, acknowledges Anapharm Bioanalytics as a world class provider of bioanalytical services to international Sponsors with its strategically located, GLP-certified and GCP-compliant laboratory in Barcelona.
With a successful regulatory history, having undergone 20 successful inspections from health agencies, including FDA (14 studies), GCP inspections from Austria, Italy and Spain (10+ studies), as well as GLP certifications by EU authorities and ANVISA (Brazil), Anapharm has become a reliable analytical partner to support its clients at any stage of drug development from preclinical throughout all clinical stages Phase I-IV.
For further details about Anapharm Bioanalytics, please visit https://www.anapharmbioanalytics.com/services/ or contact your Business Development representative at +34 93 223 8636.
MORE NEWS
Anapharm Bioanalytics Brazilian ANVISA Certificate Renewal
Anapharm Bioanalytics is proud to announce that it has recently renewed its ANVISA (Brazil) certification which is now valid until February 26th, 2026.
READ MOREAnapharm Bioanalytics Secures Funding from Eurostars and CDTI for Innovative Project on Therapy and Diagnosis of Ewing Sarcoma
Barcelona, April 18th, 2023 – Anapharm Bioanalytics, a leading bioanalytical contract research organization (CRO), is delighted to announce the successful acquisition of funding from the Eurostars-3 joint program, with co-funding from CDTI (Centre for Industrial Technological Development) and the European Union’s Horizon Europe Research and Innovation Framework. This funding marks a significant milestone for the groundbreaking project, a collaborative effort between Anapharm Bioanalytics, iCellate Medical, and Aptadel Therapeutics.
READ MOREChallenges in the Development of a Method for the Detection of Anti-PEGylated-aptamer Antibodies
Immunogenicity assays capable of properly determining the presence of anti-drug antibodies (ADA) and anti-PEG antibodies have been recognized of great importance due to the fact that pre-existing anti-PEG antibodies could have an impact on the efficacy of a drug coupled to polyethylene glycol (PEG).
READ MORE